Related Experiment Videos

Gentamicin activates rat mesangial cells. A role for platelet activating factor

A Rodriguez-Barbero1, A M Rodriguez-Lopez, R Gonzalez-Sarmiento

  • 1Instituto Reina Sofia de Investigaciones Nefrológicas, Departamento de Fisiología y Farmacología, Facultad de Medicina, Universidad de Salamanca, Spain.

Insights

Gentamicin harms kidney function by activating mesangial cells. This effect is mediated by platelet-activating factor (PAF) synthesis and release, which can be blocked by PAF antagonists.

Area of Science:

  • Nephrology
  • Cell Biology
  • Pharmacology

Background:

  • Gentamicin can decrease glomerular filtration rate.
  • This decline may involve mesangial cell contraction or vasoactive hormones.
  • Platelet-activating factor (PAF) is a potential mediator.

Purpose of the Study:

  • To investigate gentamicin's effects on mesangial cell proliferation, contraction, and calcium mobilization.
  • To assess the role of PAF in gentamicin-induced mesangial cell activation.

Main Methods:

  • Cultured rat mesangial cells were treated with gentamicin.
  • Effects on cell surface area, intracellular calcium ([Ca2+]i), and DNA synthesis ([3H]thymidine incorporation) were measured.
  • PAF synthesis, release, and c-fos mRNA expression were assessed.
  • PAF receptor antagonists (BN-52021, alprazolam, BB-823) were used to block effects.

Main Results:

  • Gentamicin reduced mesangial cell surface area, increased [Ca2+]i, and stimulated DNA synthesis.
  • These effects were blunted or inhibited by PAF antagonists.
  • Gentamicin induced c-fos mRNA expression and stimulated PAF synthesis and release from mesangial cells.

Conclusions:

  • Gentamicin activates mesangial cell functions, including proliferation and contraction.
  • Platelet-activating factor (PAF) plays a significant role in mediating gentamicin's effects on mesangial cells.
  • Targeting PAF may offer a therapeutic strategy to mitigate gentamicin-induced kidney damage.

Related Concept Videos